Remission of Follicular Non-Hodgkin's Lymphoma with Denileukin Diftitox (ONTAK ® ) After Progression During Rituximab, CHOP and Fludarabine Therapy
Author:
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,Hematology
Link
http://www.tandfonline.com/doi/pdf/10.1080/1042819031000063854
Reference5 articles.
1. National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usage
2. Follicular large cell lymphoma: Long-term follow-up of 62 patients treated between 1973–1981
3. Antitumor activity of DAB389 IL-2 fusion toxin in mycosis fungoides
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Partial Reduction of Human FOXP3+ CD4 T Cells In Vivo After CD25-directed Recombinant Immunotoxin Administration;Journal of Immunotherapy;2008-02
2. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497;Leukemia & Lymphoma;2007-01
3. Denileukin Diftitox as Novel Targeted Therapy for Lymphoid Malignancies;Cancer Investigation;2007-01
4. Non-Hodgkin's Lymphomas of Childhood;The Lymphomas;2006
5. Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma;Journal of Immunotherapy;2005-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3